Literature DB >> 12566385

Clinical and functional effects of a deletion in a COOH-terminal lumenal loop of the skeletal muscle ryanodine receptor.

Francesco Zorzato1, Naohiro Yamaguchi, Le Xu, Gerhard Meissner, Clemens R Müller, Pierre Pouliquin, Francesco Muntoni, Caroline Sewry, Thierry Girard, Susan Treves.   

Abstract

We have identified a patient affected by a relatively severe form of central core disease (CCD), carrying a heterozygous deletion (amino acids 4863-4869) in the pore-forming region of the sarcoplasmic reticulum calcium release channel. The functional effect of this deletion was investigated (i) in lymphoblastoid cells from the affected patient and her mother, who was also found to harbour the mutation and (ii) in HEK293 cells expressing recombinant mutant channels. Lymphoblastoid cells carrying the RYR1 deletion exhibit an 'unprompted' calcium release from intracellular stores, resulting in significantly smaller thapsigargin-sensitive intracellular Ca(2+) stores, compared with lymphoblastoid cells from control individuals. Blocking the RYR1 with dantrolene restored the intracellular calcium stores to levels similar to those found in control cells. Single channel and [(3)H]ryanodine binding measurements of heterologously expressed mutant channels revealed a reduced ion conductance and loss of ryanodine binding and regulation by Ca(2+). Heterologous expression of recombinant RYR1 peptides and analysis of their membrane topology demonstrate that the deleted amino acids are localized in the lumenal loop connecting membrane-spanning segments M8 and M10. We provide evidence that a deletion in the lumenal loop of RYR1 alters channel function and causes CCD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566385     DOI: 10.1093/hmg/ddg032

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

1.  Central core disease mutations R4892W, I4897T and G4898E in the ryanodine receptor isoform 1 reduce the Ca2+ sensitivity and amplitude of Ca2+-dependent Ca2+ release.

Authors:  Guo Guang Du; Vijay K Khanna; Xinghua Guo; David H MacLennan
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

2.  Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes.

Authors:  Sylvie Ducreux; Francesco Zorzato; Ana Ferreiro; Heinz Jungbluth; Francesco Muntoni; Nicole Monnier; Clemens R Müller; Susan Treves
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

3.  Changes in negative charge at the luminal mouth of the pore alter ion handling and gating in the cardiac ryanodine-receptor.

Authors:  Fiona C Mead-Savery; Ruiwu Wang; Bhavna Tanna-Topan; S R Wayne Chen; William Welch; Alan J Williams
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

4.  Calcitonin gene-related peptide restores disrupted excitation-contraction coupling in myotubes expressing central core disease mutations in RyR1.

Authors:  Ana Victoria Vega; Roberto Ramos-Mondragón; Aida Calderón-Rivera; Angel Zarain-Herzberg; Guillermo Avila
Journal:  J Physiol       Date:  2011-08-08       Impact factor: 5.182

Review 5.  Novel regulators of RyR Ca2+ release channels: insight into molecular changes in genetically-linked myopathies.

Authors:  A F Dulhunty; N A Beard; P Pouliquin; T Kimura
Journal:  J Muscle Res Cell Motil       Date:  2006-08-15       Impact factor: 2.698

Review 6.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

Review 7.  Central core disease.

Authors:  Heinz Jungbluth
Journal:  Orphanet J Rare Dis       Date:  2007-05-15       Impact factor: 4.123

8.  Variable myopathic presentation in a single family with novel skeletal RYR1 mutation.

Authors:  Ruben Attali; Sharon Aharoni; Susan Treves; Ori Rokach; Michal Becker Cohen; Yakov Fellig; Rachel Straussberg; Talya Dor; Muhannad Daana; Stella Mitrani-Rosenbaum; Yoram Nevo
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.